Study to Evaluate the Safety, Tolerability and Short Term Efficacy of Extracorporeal Specific Immunoadsorption LupusorbTM Columns for the Treatment of Systemic Lupus Erythematosus (SLE) Patients
6. Participation in another clinical trial within 2 months prior to start of this study.
7. Subject unwilling or unable to comply with the requirements of the protocol.
8. Any condition that the investigator feels would interfere with trial participation and evaluation of the results.
9. Subject unwilling and unable to provide inform consent.
10. Subjects receiving ACE inhibitors treatment 7 days prior to plasmapheresis procedure.
Clareo Health | Study to Evaluate the Safety, Tolerability and Short Term Efficacy of Extracorporeal Specific Immunoadsorption LupusorbTM Columns for the Treatment of Systemic Lupus Erythematosus (SLE) Patients
